ArticleCancer management and research2021
Primary Squamous Cell Carcinoma of the Liver is Rare but Hostile: Case Series and Comprehensive Review of the Literature.
Article in Cancer management and research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 21 citations in OpenAlex.
- Primary Hepatic Squamous Cell Carcinoma.Diagnostics (Basel, Switzerland) · 2026Article
- Primary hepatic squamous cell carcinoma with pseudoachalasia treated with TACE: Case report and literature review.Radiology case reports · 2025Article
- Immunotherapy for primary squamous cell carcinoma of the liver: A case report.Oncology letters · 2025Article
- Hepatic squamous cell carcinoma initially presenting as cholecystitis misdiagnosed as cholangiocarcinoma: A case report.Oncology letters · 2025Article
- Imaging Findings of Primary Squamous Cell Carcinoma of the Liver: Case Presentation and Literature ReviewCurrent medical imaging · 2025Review
- Article
- Article
- Primary Squamous Cell Carcinoma of the Liver.European journal of case reports in internal medicine · 2024Article
- Curative surgery for primary squamous cell carcinoma of the liver: a rare case study.Clinical journal of gastroenterology · 2023Article
- Primary hepatic squamous cell carcinoma: case report and systematic review of the literature.Frontiers in oncology · 2023Article
- Primary Squamous Cell Carcinoma of the Liver with Good Response to Carboplatin and 5-Flurouracil: A Case Report.Medicina (Kaunas, Lithuania) · 2022Article
- Primary squamous cell carcinoma of the liver: A case report.World journal of clinical cases · 2022Article
- Unexpected discovery of intrahepatic cholangiocarcinoma during follow-up in two cases of liver cysts: case report.Translational cancer research · 2022Article
- Primary squamous cell carcinoma of the liver: a case report.Gastroenterology and hepatology from bed to bench · 2022Article
- Primary Squamous Cell Carcinoma of the Liver: Case Report and Review of Literature.Case reports in oncologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary squamous cell carcinoma (SCC) of the liver is an uncommon cancer type. Only dozens of such cases have been reported in the literature. We reviewed three cases with primary SCC of the liver in a single center from January 2013 to October 2019. One case was positive for hepatitis B infection and simultaneously diagnosed with sigmoid adenocarcinoma and liver cyst. The second patient presented with hepatolithiasis. The remaining one had no history of prior liver insult, hepatic infection or any pre-existing hepatic cysts. Two cases had a long survival of more than one year through chemotherapy, or radical surgery plus transarterial chemoembolization. We also found 25 patients with primary hepatic SCC in the Surveillance, Epidemiology and End Results (SEER) database from 1997 to 2016. The median age was 67 years (range 33-87 years). The median overall survival and disease-specific survival were 7.7 months (range 0.0-76.0 months) and 2.0 months (range 0.0-20.0 months), respectively. Furthermore, patients receiving surgery had a longer median OS (20.0 versus 6.0 months,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.